TGWOOAA / Fabre-Kramer - LARVOL DELTA

Novel and promising treatments for anxiety disorders (WFSBP 2026) - "Results / Several compounds are in development, including drugs targeting the serotonin system (toludesvenlafaxine, gepirone, FKW00GA), the trace amine-associated receptor 1 (TAAR1), , the GABA binding site (ENX-102, darigabat, and buagafuran), the nicotinic receptor (soclenitant and VQW-765), the endocannabinoid system (cannabidiol and SYT-510), pherins (fasedienol) and psychedelics (MM120, PSX-001, MSP-1014). The translation of these compounds into clinically approved treatments for anxiety disorders may take several years, potentially delaying the emergence of significant therapeutic breakthroughs."

CNS Disorders • Mood Disorders • Psychiatry